Myeloprotective efficiency of combination of pyrimidine and 3-hydroxypyridine derivatives in experimental antineoplastic chemotherapy
Year: 2015, volume 11 Issue: №3 Pages: 258-262
Heading: Parmacology Article type: Original article
Authors: Siprov A.V., Masyagin V.A.
Organization: Mordovia State University n.a. N. P. Ogaryov
Heading: Parmacology Article type: Original article
Authors: Siprov A.V., Masyagin V.A.
Organization: Mordovia State University n.a. N. P. Ogaryov
Summary:
The aim of the study is comparative assessment of the influence of separated and combined use of pyrimidine and 3-hydroxypyridine derivatives — xymedon and mexidol on the bone marrow hemopoiesis and peripheral blood quantitative indicators in rats with Walker-256 carcinoma at the doxorubicin and paclitaxel chemotherapy. Materials and Methods. Experiments have been carried out on 83 Wistar female rats of weight 150-250 grams. Doxorubicin in a dose of 4mg/kg and paclitaxel in a dose of 6mg/kg were administered intraperitoneally on the 11th day of experiment. Xymedon (100mg/kg) and mexidol (50mg/kg) were administered separately and in combination with each other, starting with the 11th day of experiment for 10 Says. We estimated myelograms and peripheral blood changes on the 14th and 22d day of the experiment. Results. Xymedon normalized differentiation of granulocytopoiesis cells more effectively than mexidol and reduced severity of erythrocytopenia on the 14th day of the experiment. Combination of xymedon and mexidol accelerated granulocytes differentiation more effectively than separated use of these medicines. It was accompanied by more effective increase of neutrophils number in peripheral blood. Despite the increase of poly-chromatophil normocytes number in bone marrow to the 22d day, the erythrocytes number in blood was not differed from one at separated use of these medicines. Conclusion. Myeloprotective effect of xymedon exceeds the effect of mexidol one. The combination of xymedon and mexidol accelerates granulocytes differentiation more effectively than separated use of these medicines.
Bibliography:
1. Solntseva YV. The myelotoxic complications frequency of adjuvant chemotherapy at the breast cancer. Tyumen Medical Journal 2014; 16 (2): 47-48
2. Kinzirsky AS, Kinzirskaya YA, Zinovyev Al. The study of dicarbamin influence on the cytostatic therapy efficiency in mice with Lewis lung carcinoma. Izvestiya vysshikh uchebnykh zavedeniy: Povolzhskiy region: Meditsinskie nauki 2010; 16 (4): 44-49
3. Treshchalin ID, Bodyagin DA, Pereverzeva ER, et al. Modification of antitumor cytostatics myelosupressive action by peroral hematocorrector dicarbamin (experimental research). Voprosy-onkologii 2009; 55 (6): 769-774
4. Ivanova OV. Use of dicarbamin as a hematocorrector at leukemia drugs treatment. Voprosy-onkologii 2012; 58 (3): 416-419
5. Koroleva IA, Mochalova AS. Use of dicarbamin in patients receiving taxane chemotherapy. Voprosy-onkologii 2011; 57 (2): 250-254
6. Moiseeva IJ, Zinovyev Al, Nikishin SA, etal. The dicarbamin hematoprotective efficiency study at post-radiation bone marrow syndrome in experiment. Voprosy-onkologii 2012; 58 (1): 81-84
7. Zhukov NV Contraindications and restrictions of use for the erythropoiesis stimulating agents. Clinical Oncohematology 2009; 2 (2): 176-184
8. Kuzin VB, Lovtsova LV The influence of a ferric iron drug on lipid peroxidation in different organs of white rats. Kazanskiy meditsinskiy zhurnal 2011; 92 (2): 254-256
9. Siprov AV, Mikulyak IN, Kinzirskaya YA. Antioxidants as a medicines of hematotoxicity reducing of malignant tumors chemotherapy and radiotherapy. Penza: PSU 2012. 298 p.
10. Zobov VV, Nazarov NG, Vyshtakalyuk GB, et al. Efficiency of new pyrimidine derivatives influence on physical working capacity of rats in the test "swimming to failure". Ecological physiology 2015; (1): 28-35.
| Attachment | Size |
|---|---|
| 2015_03_258-262.pdf | 340.46 KB |
Русский
English